Active ANGPT2 protein-coupled magnetic Beads

• Cat.No.: ANGPT2-6743M

Specification

• Species: Human
• Appearance: Powder mixture
• Particle size: 2 μm
• Source: HEK293
• Protein length: Lys 275 - Phe 496
• Bio-activity: Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag with an EC50 of 3.228 μg/mL.
• Coupled amount of protein: ≈1610 pmol (47 μg) Angiopoietin-2/mg Beads.
• Capacity: >93 pmol (10 μg) Human TIE2 Protein/mg beads
• Formulation: PBS, pH7.4, with 10% Trehalose
• Reconstitution: 2 mL sterile deionized water (1 mg beads/mL)
• Background: The Human ANGPT2-coupled Magnetic Beads is produced by coupling biotinylated human angiopoietin-2/ANGPT2 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-ANGPT2 antibody or TIE2 protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.
• Application: This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
• Storage: Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Reviews

12/13/2020

The ANGPT2 protein offers exceptional quality that meets the rigorous demands of experimental research.

08/14/2020

Whether studying angiopoietin signaling pathways, vascular remodeling, or endothelial cell biology, the ANGPT2 protein is an invaluable tool for researchers.

05/15/2020

What sets the ANGPT2 protein apart is not only its outstanding quality but also the excellent technical support provided by the manufacturer.

08/18/2017

the ANGPT2 protein's versatility extends beyond its proven usefulness in in vitro experiments.

05/29/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Are there any potential side effects or risks associated with ANGPT2 inhibitors?

Like any other therapeutic agent, ANGPT2 inhibitors may have side effects and risks. Common side effects reported in clinical trials include fatigue, headache, gastrointestinal disturbances, and hypertension. However, the specific side effects and risks may vary depending on the individual drug and its mechanism of action. It is important to consult with healthcare professionals and closely monitor patients during treatment to manage any potential adverse effects.

Can ANGPT2 inhibitors be used in combination with other therapies?

Yes, ANGPT2 inhibitors can be used in combination with other therapies. Combining ANGPT2 inhibitors with other anti-angiogenic agents, chemotherapy, or immunotherapy may have synergistic effects and enhance treatment outcomes. Additionally, they may be combined with conventional treatments in diseases where ANGPT2 is implicated in disease progression or resistance to therapy. Clinical trials are ongoing to evaluate the safety and efficacy of these combination therapies.

Are there any inhibitors or activators of ANGPT2?

Several compounds have been identified as inhibitors of ANGPT2. These include antibodies that specifically target ANGPT2, as well as small molecule inhibitors that interfere with its activity. In contrast, there are no known activators of ANGPT2 identified to date.

Are there natural compounds or dietary factors that can modulate ANGPT2 levels?

Some studies suggest that certain natural compounds or dietary factors can modulate ANGPT2 levels. For example, green tea catechins, resveratrol, and curcumin have demonstrated potential in reducing ANGPT2 expression or activity in preclinical studies. However, more research is needed to determine their efficacy and safety in clinical settings.

Are there any genetic or epigenetic factors that regulate ANGPT2 expression?

Yes, ANGPT2 expression is regulated by various genetic and epigenetic factors. Single nucleotide polymorphisms (SNPs) in the ANGPT2 gene have been associated with altered ANGPT2 expression levels and susceptibility to certain diseases. Additionally, epigenetic modifications, such as DNA methylation and histone modifications, can also regulate ANGPT2 expression by influencing the accessibility of the gene for transcription.

What are the challenges and future directions in the development and use of ANGPT2 inhibitors?

One of the challenges in the development and use of ANGPT2 inhibitors is identifying the patient populations that would benefit most from this therapy. Understanding the precise mechanisms of ANGPT2 in different diseases and identifying reliable biomarkers for patient selection are important areas of future research.

What are the potential therapeutic applications of ANGPT2 inhibitors?

ANGPT2 inhibitors have shown promise in various therapeutic applications. In cancer, blocking ANGPT2 can help normalize tumor blood vessels, improve drug delivery to the tumor, and enhance the effectiveness of anti-cancer therapies. Additionally, ANGPT2 inhibitors may also have potential in the treatment of other diseases involving abnormal angiogenesis, such as age-related macular degeneration, diabetic retinopathy, and inflammatory disorders.

What role does ANGPT2 play in cancer?

In cancer, ANGPT2 is often upregulated and contributes to tumor angiogenesis and progression. It promotes vessel destabilization, allowing for the formation of leaky and irregular blood vessels within tumors. This abnormal vasculature can support tumor growth, metastasis, and resistance to therapies.

Are there ongoing clinical trials targeting ANGPT2 in cancer or other diseases?

Yes, there are ongoing clinical trials investigating the therapeutic potential of targeting ANGPT2 in cancer and other diseases. These trials evaluate the efficacy and safety of ANGPT2 inhibitors either alone or in combination with other treatments. These studies aim to elucidate whether blocking ANGPT2 can have clinical benefits, such as inhibiting tumor growth, improving patient outcomes, or overcoming therapy resistance.

Can ANGPT2 be used as a biomarker in diseases?

ANGPT2 has been explored as a potential biomarker in various diseases, including cancer, cardiovascular diseases, and sepsis. Elevated levels of ANGPT2 have been associated with disease progression and poor prognosis in some cases. However, further research is still needed to establish its clinical utility as a diagnostic or prognostic biomarker.

How is ANGPT2 involved in inflammation and immune responses?

ANGPT2 plays a role in inflammation and immune responses by promoting vascular leakiness and enhancing the recruitment of immune cells to the site of inflammation. It is produced by immune cells, such as macrophages and neutrophils, in response to inflammatory stimuli. ANGPT2 can disrupt endothelial integrity, facilitating the extravasation of immune cells and contributing to the inflammatory process.

Are there any therapeutic strategies aimed at restoring the balance between ANGPT1 and ANGPT2?

Yes, some therapeutic strategies aim to restore the balance between ANGPT1 and ANGPT2. These strategies include the administration of exogenous ANGPT1 or ANGPT2 inhibitors to regulate angiogenesis and vascular stability. The goal is to promote a more balanced and controlled angiogenic response, which may have therapeutic benefits in various diseases characterized by aberrant angiogenesis.

Are there any ongoing clinical trials investigating the use of ANGPT2 inhibitors in different diseases?

Yes, there are several ongoing clinical trials investigating the use of ANGPT2 inhibitors in various diseases. These trials assess the safety, efficacy, and optimal dosing of ANGPT2 inhibitors either as monotherapy or in combination with other treatments. Some of the diseases being studied include solid tumors, diabetic macular edema, acute myeloid leukemia, and idiopathic pulmonary fibrosis, among others. These trials aim to determine the potential of ANGPT2 inhibitors as a therapeutic option in these diseases.

How do ANGPT2 inhibitors compare to other anti-angiogenic therapies?

ANGPT2 inhibitors function as anti-angiogenic agents by blocking the activation of ANGPT2 and its interaction with the Tie2 receptor. Compared to other anti-angiogenic therapies, such as VEGF inhibitors, ANGPT2 inhibitors target a different pathway involved in angiogenesis regulation.

Where is ANGPT2 produced?

ANGPT2 is produced by various cell types, including endothelial cells, immune cells, and certain cancer cells. Its production can be induced by different stimuli, such as hypoxia, inflammation, and growth factors.